Current Problems in Surgery
Volume 45, Issue 8 , Pages 527-575 , August 2008

Pseudomyxoma Peritonei

  • Robert M. Smeenk, MD, PhD

      Affiliations

    • Resident in General Surgery, Academic Medical Hospital, Amsterdam, The Netherlands
    • ,
  • Sjoerd C. Bruin, MD

      Affiliations

    • Clinical Fellow, Departments of Molecular Pathology and Surgical Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • Marie-Louise F. van Velthuysen, MD, PhD

      Affiliations

    • Attending in Pathology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • Victor J. Verwaal, MD, PhD

      Affiliations

    • Surgical Oncologist, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands

References 

  1. Limber GK, King RE, Silverberg SG. Pseudomyxoma peritonaei: a report of ten cases. Ann Surg. 1973;178:587–593
  2. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233–280
  3. Werth R. Klinische und anatomische untersuchungen zur lehre von den bauchgeschwuelsten und der laparotomie. Arch Gynaecol Obstet. 1884;24:100–118
  4. Fraenkel E. Ueber das sogennante pseudomyxoma peritonei. Munch Med Wochenschr. 1901;48:965–971
  5. Weaver CH. Mucocele of the appendix with pseudomucinous degeneration. Am J Surg. 1937;36:523
  6. Cheng KK. An experimental study of mucocele of the appendix and pseudomyxoma peritonei. J Pathol Bacteriol. 1949;61:217–2254 pl.
  7. Sandenbergh HA, Woodruff JD. Histogenesis of pseudomyxoma peritonei (Review of 9 cases). Obstet Gynecol. 1977;49:339–345
  8. Hughes J. Mucocele of the appendix with pseudomyxoma peritonei: a benign or malignant disease?. Ann Surg. 1967;165:73–76
  9. Smith GE. Studies in the anatomy of the pelvis, with special reference to the fasciae and visceral supports: part I. J Anat Physiol. 1908;42:198–218
  10. Myer MW. A malignant type of pseudomyxoma peritonei penetrating the spleen and colon. Ann Surg. 1907;45:838–851
  11. Byron RL, Yonemoto RH, King RM, et al. The management of pseudomyxoma peritonei secondary to ruptured mucocele of the appendix. Surg Gynecol Obstet. 1966;122:509–512
  12. Muller G, Dirschmid K, Breitfellner G, et al. [Clinical aspects of pseudomyxoma peritonei]. Chirurg. 1984;55:32–36
  13. Friedland JS, Allardice JT, Wyatt AP. Pseudomyxoma peritonei. J R Soc Med. 1986;79:480–482
  14. Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei (A clinicopathological analysis of 22 cases supporting an origin in the appendix). Am J Surg Pathol. 1991;15:415–429
  15. Seidman JD, Elsayed AM, Sobin LH, et al. Association of mucinous tumors of the ovary and appendix (A clinicopathologic study of 25 cases). Am J Surg Pathol. 1993;17:22–34
  16. Prayson RA, Hart WR, Petras RE. Pseudomyxoma peritonei (A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors). Am J Surg Pathol. 1994;18:591–603
  17. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis (A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.”). Am J Surg Pathol. 1995;19:1390–1408
  18. Sugarbaker PH, Zhu BW, Sese GB, et al. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. 1993;36:323–329
  19. O'Connell JT, Tomlinson JS, Roberts AA, et al. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol. 2002;161:551–564
  20. Grodinsky M, Rubnitz AS. Mucocele of the appendix and pseudomyxoma peritonei: a clinical review and experimental study, with case report. Surg Gynecol Obstet. 1941;73:345–354
  21. Sugarbaker PH. Pseudomyxoma peritonei (A cancer whose biology is characterized by a redistribution phenomenon). Ann Surg. 1994;219:109–111
  22. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990;4:2868–2880
  23. Lee BY, Kim HS, Lee SH, et al. Pseudomyxoma peritonei: extraperitoneal spread to the pleural cavity and lung. J Thorac Imaging. 2004;19:123–126
  24. Mortman KD, Sugarbaker PA, Shmookler BM, et al. Pulmonary metastases in pseudomyxoma peritonei syndrome. Ann Thorac Surg. 1997;64:1434–1436
  25. Geisinger KR, Levine EA, Shen P, et al. Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review. Am J Clin Pathol. 2007;127:135–143
  26. Peek DF, Beets GL. Pseudomyxoma peritonei in the pleural cavity: report of a case. Dis Colon Rectum. 1999;42:113–115
  27. Yoshida R, Yoshioka K, Yoshitaka H, et al. Pseudomyxoma peritonei of appendiceal cancer with metastasis to the stomach: report of a case. Surg Today. 2002;32:547–550
  28. Smeenk RM, Verwaal VJ, Antonini N, et al. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol. 2007;14:493–499
  29. Mets T, Van Hove W, Louis H. Pseudomyxoma peritonei (Report of a case with extraperitoneal metastasis and invasion of the spleen). Chest. 1977;72:792–794
  30. Bradley RF, Stewart JH, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–559
  31. Mukherjee A, Parvaiz A, Cecil TD, et al. Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur J Gynaecol Oncol. 2004;25:411–414
  32. Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol. 2004;21:134–150
  33. Sherer DM, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature. Gynecol Obstet Invest. 2001;51:73–80
  34. Smeenk RM, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei. Cancer Treat Rev. 2007;33:138–145
  35. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol. 1997;16:1–9
  36. Smeenk RM, Bex A, Verwaal VJ, et al. Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol. 2006;93:20–23
  37. Chejfec G, Rieker WJ, Jablokow VR, et al. Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology. 1986;90:202–205
  38. de Bree E, Witkamp A, Van De Vijver M, et al. Unusual origins of pseudomyxoma peritonei. J Surg Oncol. 2000;75:270–274
  39. Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849–1855
  40. Guerrieri C, Franlund B, Fristedt S, et al. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum Pathol. 1997;28:1039–1045
  41. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Hum Pathol. 1996;27:165–171
  42. Cuatrecasas M, Matias-Guiu X, Prat J. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei (A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations). Am J Surg Pathol. 1996;20:739–746
  43. Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196–201
  44. Ronnett BM, Kurman RJ, Zahn CM, et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol. 1995;26:509–524
  45. Ronnett BM, Shmookler BM, Sugarbaker PH, et al. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol. 1997;2:197–226
  46. van ES, Offerhaus GJ, Hart AA, et al. Goblet cell carcinoid of the appendix: a specific type of carcinoma. Histopathology. 2007;51:763–773
  47. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001;92:85–91
  48. Cariker M, Dockerty M. Mucinous cystadenomas and mucinous cystadenocarcinomas of the ovary; a clinical and pathological study of 355 cases. Cancer. 1954;7:302–310
  49. Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104–109
  50. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526–534
  51. Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–634
  52. Deraco M, Kusamura S, Laterza B, et al. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. In Vivo. 2006;20:773–776
  53. Jacquemin G, Laloux P. Pseudomyxoma peritonei: review on a cluster of peritoneal mucinous diseases. Acta Chir Belg. 2005;105:127–133
  54. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–132
  55. Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12:585–603
  56. Kang H, O'Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48:1161–1168
  57. Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum. 2003;46:160–167
  58. Nozoe T, Anai H, Nasu S, et al. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol. 2000;75:103–107
  59. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer. 1995;75:154–170
  60. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–130
  61. Darnis E, Ronceray J, Grosieux P, et al. [Pseudomyxoma peritonei in females. 13 personal cases. Practical deductions from a review of 420 cases in the literature]. J Gynecol Obstet Biol Reprod (Paris). 1987;16:343–353
  62. Mann WJ, Wagner J, Chumas J, et al. The management of pseudomyxoma peritonei. Cancer. 1990;66:1636–1640
  63. McCusker ME, Cote TR, Clegg LX, et al. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer. 2002;94:3307–3312
  64. Nielsen GP, Isaksson HJ, Finnbogason H, et al. Adenocarcinoma of the vermiform appendix (A population study). APMIS. 1991;99:653–656
  65. Esquivel J, Sugarbaker PH. Clinical presentation of the pseudomyxoma peritonei syndrome. Br J Surg. 2000;87:1414–1418
  66. Shinohara T, Misawa K, Sano H, et al. Pseudomyxoma peritonei due to mucinous cystadenocarcinoma in situ of the urachus presenting as an inguinal hernia. Int J Clin Oncol. 2006;11:416–419
  67. Esquivel J, Sugarbaker PH. Pseudomyxoma peritonei in a hernia sac: analysis of 20 patients in whom mucoid fluid was found during a hernia repair. Eur J Surg Oncol. 2001;27:54–58
  68. Edwards DP, Scott HJ. The use of laparoscopy in a case of appendiceal cystadenoma presenting as pseudomyxoma peritonei in an inguinal hernial sac. J R Coll Surg Edinb. 1998;43:112–113
  69. Rezkalla MA, Peterson KG, Ryan JJ. Pseudomyxoma peritonei: a case of mucinous adenocarcinoma of the appendix presenting as inguinal hernia. S D Med. 2006;59:54–5557.
  70. Skaane P, Isachsen MM, Hoiseth A. Computed tomography of mucin-producing adenocarcinoma of the appendix presenting as a bladder tumor. J Comput Assist Tomogr. 1985;9:566–567
  71. Deture FA, Madorsky ML, Deardourff SL. Adenocarcinoma of the appendix—a rare cause of right ureteral obstruction. J Urol. 1976;116:514–515
  72. Solkar MH, Akhtar NM, Khan Z, et al. Pseudomyxoma extraperitonei occurring 35 years after appendicectomy: a case report and review of literature. World J Surg Oncol. 2004;2:19
  73. Taii A, Sakagami J, Shinoda M, et al. Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy. Intern Med. 2007;46:1109–1112
  74. Ruiz-Tovar J, Teruel DG, Castineiras VM, et al. Mucocele of the appendix. World J Surg. 2007;31:542–548
  75. Thompson MA, Ashton RW, Pitot HC. Mucinous appendiceal adenocarcinoma presenting 5 years after appendectomy. Ann Intern Med. 2004;140:W33
  76. Vana J, Adamicova K, Johanes R, et al. [Appendiceal mucocele causing pseudomyxoma peritonei]. Zentralbl Chir. 2005;130:177–180
  77. Francica G, Lapiccirella G, Giardiello C, et al. Giant mucocele of the appendix: clinical and imaging findings in 3 cases. J Ultrasound Med. 2006;25:643–648
  78. Hanbidge AE, Lynch D, Wilson SR. US of the peritoneum. Radiographics. 2003;23:663–684
  79. Tsai CJ. Ultrasound features of disseminated adenomucinosis (pseudomyxoma). Br J Radiol. 1998;71:564–566
  80. Bechtold RE, Chen MY, Loggie BW, et al. CT appearance of disseminated peritoneal adenomucinosis. Abdom Imaging. 2001;26:406–410
  81. Kreel L, Bydder GM. Computed tomography of fluid collections within the abdomen. J Comput Tomogr. 1980;4:105–115
  82. Sulkin TV, O'Neill H, Amin AI, et al. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol. 2002;57:608–613
  83. de Bree E, Koops W, Kroger R, et al. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2006;32:65–71
  84. Buy JN, Malbec L, Ghossain MA, et al. Magnetic resonance imaging of pseudomyxoma peritonei. Eur J Radiol. 1989;9:115–118
  85. Gollub MJ, DeCorato D, Schwartz LH. MR enteroclysis: evaluation of small-bowel obstruction in a patient with pseudomyxoma peritonei. AJR Am J Roentgenol. 2000;174:688–690
  86. Yang QM, Bando E, Kawamura T, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho. 2006;33:1817–1821
  87. Kairemo KJ, Jekunen AP, Bondestam S, et al. Detection of pseudomyxoma peritonei by radioimmunohistochemistry and radioimmunoscintigraphy. Cancer Biother Radiopharm. 1996;11:325–334
  88. Lersch C, Frimberger E, Ott R, et al. Gray-scale sonographic findings in a patient with pseudomyxoma peritonei. J Clin Ultrasound. 2001;29:186–191
  89. Raj J, Urban LM, ReMine SG, et al. Laparoscopic management of pseudomyxoma peritonei secondary to adenocarcinoma of the appendix. J Laparoendosc Adv Surg Tech A. 1999;9:299–303
  90. Carmignani CP, Hampton R, Sugarbaker CE, et al. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 2004;87:162–166
  91. van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2002;9:961–967
  92. Baratti D, Kusamura S, Martinetti A, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:2300–2308
  93. Alexander-Sefre F, Chandrakumaran K, Banerjee S, et al. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis. 2005;7:382–386
  94. Nonaka D, Kusamura S, Baratti D, et al. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology. 2006;49:381–387
  95. Semino-Mora C, Liu H, McAvoy T, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? (A study of bacteria, MUC2 and MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis). Ann Surg Oncol. 2008;15:1414–1423
  96. Bibi R, Pranesh N, Saunders MP, et al. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer. 2006;95:1258–1264
  97. Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg. 2004;91:304–311
  98. Galani E, Marx GM, Steer CB, et al. Pseudomyxoma peritonei: the ‘controversial’ disease. Int J Gynecol Cancer. 2003;13:413–418
  99. Little JM, Halliday JP, Gleen DC. Pseudomyxoma peritonei. Lancet. 1969;2:846
  100. Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg. 2005;
  101. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei (Long-term patient survival with an aggressive regional approach). Ann Surg. 1994;219:112–119
  102. Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin (The Memorial Sloan-Kettering Cancer Center experience). Cancer. 1992;70:396–401
  103. Zoetmulder FA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer. 1996;32A:1727–1733
  104. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–308
  105. Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy with peritoneal spread of cystadenocarcinoma. Eur J Surg Suppl. 1991;75–82
  106. Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–492
  107. Verwaal VJ, van Tinteren H, Ruth SV, et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61–67
  108. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12:703–727xiii.
  109. Sugarbaker PH. Laser-mode electrosurgery. Cancer Treat Res. 1996;82:375–385
  110. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol. 1994;10:12–20
  111. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–3292
  112. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27:239–243
  113. Witkamp AJ, de Bree E, Van Goethem R, et al. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27:365–374
  114. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11
  115. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63
  116. Sugarbaker PH, Landy D, Jaffe G, et al. Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. Cancer. 1990;65:1495–1501
  117. Los G, Smals OA, van Vugt MJ, et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 1992;52:1252–1258
  118. Jacquet P, Vidal-Jove J, Zhu B, et al. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg. 1994;94:191–197
  119. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg. 2001;88:458–463
  120. van Ruth S, Mathot RA, Sparidans RW, et al. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet. 2004;43:131–143
  121. van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771–780
  122. Butterworth SA, Panton ON, Klaassen DJ, et al. Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg. 2002;183:529–532
  123. Yan TD, Links M, Xu ZY, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg. 2006;93:1270–1276
  124. Elias D, Laurent S, Antoun S, et al. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]. Gastroenterol Clin Biol. 2003;27:407–412
  125. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50:37–42
  126. van Leeuwen BL, Graf W, Pahlman L, et al. Swedish experience with peritonectomy and HIPEC (HIPEC in peritoneal carcinomatosis). Ann Surg Oncol. 2008;15:745–753
  127. Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–190
  128. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393–398
  129. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–796
  130. Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2005;48:1372–1379
  131. Jacquet P, Jelinek JS, Chang D, et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg. 1995;181:530–538
  132. Moran BJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf). 2006;28:375–378
  133. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408–1414
  134. Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14:2270–2280
  135. Cavaliere F, Valle M, De RB, et al. [Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve]. Suppl Tumori. 2005;4:S119–S121
  136. Gonzalez-Moreno S. Peritoneal surface oncology: a progress report. Eur J Surg Oncol. 2006;32:593–596
  137. Haid M, Bowie L, Kim D, et al. Peritoneal washing therapy for pseudomyxoma peritonei. South Med J. 1981;74:913–915
  138. Green N, Gancedo H, Smith R, et al. Pseudomyxoma peritonei-nonoperative management and biochemical findings (A case report). Cancer. 1975;36:1834–1837
  139. Piver MS, Lele SB, Patsner B. Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavage. Obstet Gynecol. 1984;64:95S–96S
  140. Machado MA, Rodrigues JG, Laurino RM, et al. [Conservative treatment of pseudomyxoma peritonei]. Rev Hosp Clin Fac Med Sao Paulo. 1993;48:301–304
  141. Sindelar WF, DeLaney TF, Tochner Z, et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms (Phase I study). Arch Surg. 1991;126:318–324
  142. Fernandez RN, Daly JM. Pseudomyxoma peritonei. Arch Surg. 1980;115:409–414
  143. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959
  144. Lang H, Jahne J, Flemming P, et al. Pseudomyxoma peritonei of appendiceal origin–a report of seven cases and a review of published reports. Eur J Surg. 1995;161:355–360
  145. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–731
  146. Scuderi S, Costamagna D, Vaira M, et al. [Treatment of pseudomyxoma peritonei using cytoreduction and intraperitoneal hyperthermic chemotherapy]. Tumori. 2003;89:43–45
  147. Guner Z, Schmidt U, Dahlke MH, et al. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis. 2005;20:155–160
  148. De Simone M, Vaira M, Caponi A, et al. Ten years experience in the treatment of pseudomyxoma peritonei by cytoreduction, peritonectomy and semi-closed hyperthermic antiblastic peritoneal perfusion. In Vivo. 2006;20:725–727
  149. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14:2289–2299
  150. Sugarbaker PH, Fernandez-Trigo V, Shamsa F. Clinical determinants of treatment failure in patients with pseudomyxoma peritonei. Cancer Treat Res. 1996;81:121–132
  151. Miner TJ. The impact of therapy in the treatment of pseudomyxoma peritonei. Cancer Treat Res. 2007;134:329–342
  152. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?. Lancet Oncol. 2006;7:69–76
  153. Esquivel J, Sugarbaker PH. Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg. 2001;234:198–205
  154. Sugarbaker PH. The natural history, gross pathology, and histopathology of appendiceal epithelial neoplasms. Eur J Surg Oncol. 2006;32:644–647
  155. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2:3
  156. Sugarbaker PH. Peritoneal surface oncology: review of a personal experience with colorectal and appendieal malignancy. Tech Coloproctol. 2005;9:95–103
  157. van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res. 2003;23:1501–1508

PII: S0011-3840(08)00071-3

doi: 10.1067/j.cpsurg.2008.04.003

Current Problems in Surgery
Volume 45, Issue 8 , Pages 527-575 , August 2008

Article Tools

* Image Usage & Resolution